KR101697800B1 - 니타족사니드의 서방성 제약 제형 - Google Patents

니타족사니드의 서방성 제약 제형 Download PDF

Info

Publication number
KR101697800B1
KR101697800B1 KR1020117020973A KR20117020973A KR101697800B1 KR 101697800 B1 KR101697800 B1 KR 101697800B1 KR 1020117020973 A KR1020117020973 A KR 1020117020973A KR 20117020973 A KR20117020973 A KR 20117020973A KR 101697800 B1 KR101697800 B1 KR 101697800B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
layer
amount
composition
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117020973A
Other languages
English (en)
Korean (ko)
Other versions
KR20120008024A (ko
Inventor
장-프랑수아 로시그놀
마크 에어즈
Original Assignee
로마크 레버러토리즈, 엘.씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로마크 레버러토리즈, 엘.씨. filed Critical 로마크 레버러토리즈, 엘.씨.
Publication of KR20120008024A publication Critical patent/KR20120008024A/ko
Application granted granted Critical
Publication of KR101697800B1 publication Critical patent/KR101697800B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020117020973A 2009-02-13 2010-02-12 니타족사니드의 서방성 제약 제형 Expired - Fee Related KR101697800B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20228509P 2009-02-13 2009-02-13
US61/202,285 2009-02-13
PCT/US2010/024000 WO2010093854A1 (en) 2009-02-13 2010-02-12 Controlled release pharmaceutical formulations of nitazoxanide

Publications (2)

Publication Number Publication Date
KR20120008024A KR20120008024A (ko) 2012-01-25
KR101697800B1 true KR101697800B1 (ko) 2017-01-18

Family

ID=42560126

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117020973A Expired - Fee Related KR101697800B1 (ko) 2009-02-13 2010-02-12 니타족사니드의 서방성 제약 제형

Country Status (23)

Country Link
US (5) US8524278B2 (https=)
EP (1) EP2395840B1 (https=)
JP (3) JP5726766B2 (https=)
KR (1) KR101697800B1 (https=)
CN (2) CN102395276A (https=)
AU (3) AU2010213678B2 (https=)
BR (1) BRPI1007945C8 (https=)
CA (1) CA2752233C (https=)
CO (1) CO6501159A2 (https=)
CY (1) CY1123162T1 (https=)
DK (1) DK2395840T3 (https=)
EA (1) EA029018B1 (https=)
ES (1) ES2797493T3 (https=)
HR (1) HRP20201055T1 (https=)
HU (1) HUE049501T2 (https=)
IL (1) IL214624A0 (https=)
LT (1) LT2395840T (https=)
MX (2) MX381895B (https=)
PL (1) PL2395840T3 (https=)
PT (1) PT2395840T (https=)
SI (1) SI2395840T1 (https=)
UA (1) UA107564C2 (https=)
WO (1) WO2010093854A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US8524278B2 (en) 2009-02-13 2013-09-03 Romark Laboratories L.C. Controlled release pharmaceutical formulations of nitazoxanide
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
WO2013124768A1 (en) * 2012-02-20 2013-08-29 Lupin Limited Bilayer tablet of dronedarone
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
CN107105660A (zh) 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
CN108289961A (zh) 2016-03-31 2018-07-17 罗马克实验室有限公司 用于治疗病毒性感染的噻唑化物化合物
CN109152760B (zh) * 2016-04-11 2022-09-23 基恩菲特公司 胆汁淤积性和纤维化疾病的治疗方法
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
EA201992116A1 (ru) * 2017-03-08 2020-01-29 СИНРКС ФАРМА, ЭлЭлСи Фармацевтические составы флороглюцинола и триметилфлороглюцинола
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
CN108524460B (zh) * 2018-05-14 2021-01-01 佛山市南海东方澳龙制药有限公司 烯啶虫胺双层片
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
CN110025621A (zh) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 替唑尼特和硝唑尼特在制备抗炎药物中的应用
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
JP2023510140A (ja) * 2019-12-19 2023-03-13 セルトリオン， インク． シベンゾリンまたはその塩を含む薬学剤形
EP4182304A1 (en) 2020-07-20 2023-05-24 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
MX2023002208A (es) 2020-08-24 2023-05-17 Romark Laboratories Lc Uso de tiazolidas contra los coronavirus.
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease
DE112022004799T5 (de) 2021-10-05 2024-08-14 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) Verbessertes Verfahren zur Herstellung von Nitazoxanid und Zwischenprodukten davon
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508327A (ja) 2001-09-28 2005-03-31 マクニール−ピーピーシー・インコーポレイテッド 改質した放出用の投薬形態
US20060141037A1 (en) 2004-12-29 2006-06-29 J. B. Chemicals & Pharmaceuticals Ltd. Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20070167504A1 (en) * 2006-01-09 2007-07-19 Jean-Francois Rossignol Viral hepatitis treatment
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
ES2232687T3 (es) * 1997-05-07 2005-06-01 Romark Laboratories, L.C. Composiciones farmaceuticas de tizoxanida y/o nitazoxanida.
US5948440A (en) 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4637338B2 (ja) 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
AU2357202A (en) 2000-09-29 2002-04-08 Solvay Pharm Bv Ion-strength independent sustained release pharmaceutical formulation
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US20040202718A1 (en) 2001-09-28 2004-10-14 Tyebji Ziauddin Z. Dosage form for treatment of diabetes mellitus
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
PE20050335A1 (es) 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
JP2006335771A (ja) * 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
US20080286344A1 (en) * 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
US8524278B2 (en) * 2009-02-13 2013-09-03 Romark Laboratories L.C. Controlled release pharmaceutical formulations of nitazoxanide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508327A (ja) 2001-09-28 2005-03-31 マクニール−ピーピーシー・インコーポレイテッド 改質した放出用の投薬形態
US20060141037A1 (en) 2004-12-29 2006-06-29 J. B. Chemicals & Pharmaceuticals Ltd. Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20070167504A1 (en) * 2006-01-09 2007-07-19 Jean-Francois Rossignol Viral hepatitis treatment
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug

Also Published As

Publication number Publication date
BRPI1007945A2 (pt) 2015-09-01
EP2395840A1 (en) 2011-12-21
CO6501159A2 (es) 2012-08-15
EA029018B1 (ru) 2018-01-31
EA201190127A1 (ru) 2012-03-30
AU2010213678B2 (en) 2015-11-26
JP5726766B2 (ja) 2015-06-03
CN107260695A (zh) 2017-10-20
CY1123162T1 (el) 2021-10-29
IL214624A0 (en) 2011-09-27
CN102395276A (zh) 2012-03-28
EP2395840B1 (en) 2020-04-15
WO2010093854A1 (en) 2010-08-19
AU2016200971A1 (en) 2016-03-03
US20160243087A1 (en) 2016-08-25
US20180085353A1 (en) 2018-03-29
EP2395840A4 (en) 2013-12-25
MX381895B (es) 2025-03-13
US20140065215A1 (en) 2014-03-06
BRPI1007945B8 (pt) 2020-08-18
PT2395840T (pt) 2020-07-06
ES2797493T3 (es) 2020-12-02
US9351937B2 (en) 2016-05-31
US10383855B2 (en) 2019-08-20
AU2016200971B2 (en) 2017-02-23
HRP20201055T1 (hr) 2020-10-30
DK2395840T3 (da) 2020-06-08
UA107564C2 (uk) 2015-01-26
JP6117845B2 (ja) 2017-04-19
US20190321338A1 (en) 2019-10-24
BRPI1007945C8 (pt) 2021-05-25
AU2017203148A1 (en) 2017-06-01
MX2011008530A (es) 2011-10-14
JP2017061561A (ja) 2017-03-30
KR20120008024A (ko) 2012-01-25
CA2752233C (en) 2017-01-03
AU2010213678A1 (en) 2011-09-01
PL2395840T3 (pl) 2020-09-07
US11426388B2 (en) 2022-08-30
JP2015143258A (ja) 2015-08-06
US20100209505A1 (en) 2010-08-19
HUE049501T2 (hu) 2020-09-28
SI2395840T1 (sl) 2020-08-31
US9827227B2 (en) 2017-11-28
BRPI1007945B1 (pt) 2020-08-04
AU2017203148B2 (en) 2018-08-09
CA2752233A1 (en) 2010-08-19
JP6491174B2 (ja) 2019-03-27
LT2395840T (lt) 2020-07-10
JP2012518002A (ja) 2012-08-09
US8524278B2 (en) 2013-09-03
MX348282B (es) 2017-06-05
BRPI1007945C1 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
KR101697800B1 (ko) 니타족사니드의 서방성 제약 제형
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
KR100757155B1 (ko) 저용량의 엔테카비르 제제 및 그의 용도
KR102240240B1 (ko) 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
JP2012518002A5 (https=)
US20240041882A1 (en) Mini-tablet dosage form of a viral terminase inhibitor and uses thereof
CN118236367A (zh) 一种复方制剂及其制备方法
HK1165217A (en) Controlled release pharmaceutical formulations of nitazoxanide
HK1165217B (en) Controlled release pharmaceutical formulations of nitazoxanide
CN112843053A (zh) Ns5a抑制剂组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220113

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220113